A phase II study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in patients with HER2-positive metastatic solid tumors and metastases to brain (TUCATEMEB)

被引：0
|
作者：
Dumbrava, Ecaterina E.
Kennon, Amber M.
Murthy, Rashmi K.
Montazari, Emma J.
Tawbi, Hussein
Li, Jing
Lang, Frederick F.
Sanchez, Gisela
Wang, Jianbo
Glitza, Isabella C.
O'Brien, Barbara J.
Beckham, Thomas
Swanson, Todd
Tom, Martin C.
Vu, Uyen M.
Darko, Tanisha T.
Cai, Tiantian
Shah, Komal
Meric-Bernstam, Funda
Rodon, Jordi
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2024-CT289
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT289
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Ado-trastuzumab emtansine (T-DM1) is effective against established HER2-positive breast cancer brain metastases in mice
    Askoxylakis, V.
    Ferraro, G.
    Kodack, D.
    Badeaux, M.
    Jain, R.
    CANCER RESEARCH, 2016, 76
  • [2] Ado-trastuzumab emtansine (T-DM1) controls tumor progression of established HER2-positive breast cancer brain metastases in mice
    Ferraro, Gino B.
    Askoxylakis, Vasileios
    Kodack, David P.
    Badeaux, Mark
    Fukumura, Dai
    Engelman, Jeffrey A.
    Jain, Rakesh K.
    CANCER RESEARCH, 2016, 76
  • [3] Trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer and brain metastases
    Jacot, W.
    Pons, E.
    Guiu, S.
    Levy, C.
    Frenel, J-S
    Bachelot, T.
    D'Hondt, V.
    Firmin, N.
    Romieu, G.
    Thezenas, S.
    Dalenc, F.
    CANCER RESEARCH, 2016, 76
  • [4] Ado-trastuzumab emtansine (T-DM1): a novel antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer
    Baron, Jessica M.
    Boster, Bonnie L.
    Barnett, Chad M.
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2015, 21 (02) : 132 - 142
  • [5] Ado-trastuzumab Emtansine (T-DM1): An Antibody-Drug Conjugate (ADC) for HER2-Positive Breast Cancer
    Lambert, John M.
    Chari, Ravi V. J.
    JOURNAL OF MEDICINAL CHEMISTRY, 2014, 57 (16) : 6949 - 6964
  • [6] Role of ado-trastuzumab emtansine (T-DM1) in HER2 positive salivary gland tumour with brain metastasis
    Dhamne, Nilesh
    Koyyala, Venkata Pradeep Babu
    Chougule, Snehal
    Pawar, Suraj
    BMJ CASE REPORTS, 2022, 15 (05)
  • [7] Liquid biopsy and Ado-trastuzumab emtansine (T-DM1): drug-resistance traits in the blood of HER2-positive metastatic breast cancer patients
    Fabi, Alessandra
    Allegretti, Matteo
    Giordani, Elena
    Ferretti, Gianluigi
    Arpino, Grazia
    Zambelli, Alberto
    Omarini, Claudia
    Paris, Ida
    Botticelli, Andrea
    Bria, Emilio
    Palazzo, Antonella
    Gori, Stefania
    Cognetti, Francesco
    Giacomini, Patrizio
    CANCER RESEARCH, 2023, 83 (05)
  • [8] Safety, efficacy and survival outcome of Ado-trastuzumab emtansine (T-DM1) in patients with metastatic HER2-positive breast cancer: An Indian experience.
    Gogia, Ajay
    Gupta, Anshul
    Deo, S. V. S.
    Sharma, Dayanand
    Mathur, Sandeep
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [9] ERBB2mRNA Expression and Response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer
    Griguolo, Gaia
    Braso-Maristany, Fara
    Gonzalez-Farre, Blanca
    Pascual, Tomas
    Chic, Nuria
    Sauri, Tamara
    Kates, Ronald
    Gluz, Oleg
    Martinez, Debora
    Pare, Laia
    Tsvetkova, Vassilena
    Pesantez, David
    Vidal, Maria
    Adamo, Barbara
    Munoz, Montserrat
    Galvan, Patricia
    Barbera, Laura
    Cuatrecasas, Miriam
    Christgen, Mathias
    Kreipe, Hans
    Monge-Escartin, Ines
    Villagrasa, Patricia
    Soy, Dolors
    Giarratano, Tommaso
    Dieci, Maria Vittoria
    Conte, Pierfranco
    Harbeck, Nadia
    Guarneri, Valentina
    Prat, Aleix
    CANCERS, 2020, 12 (07) : 1 - 25
  • [10] Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases
    Jacot, William
    Pons, Elvire
    Frenel, Jean-Sebastien
    Guiu, Severine
    Levy, Christelle
    Heudel, Pierre Etienne
    Bachelot, Thomas
    D'Hondt, Veronique
    Darlix, Amelie
    Firmin, Nelly
    Romieu, Gilles
    Thezenas, Simon
    Dalenc, Florence
    BREAST CANCER RESEARCH AND TREATMENT, 2016, 157 (02) : 307 - 318
12345